XAIR

Beyond Air, Inc.'s stock (XAIR) has experienced several notable events in the past six months. The company reported mixed Q2 and Q3 2026 earnings, with EPS missing estimates but revenue sometimes beating expectations. Dan Moorhead was appointed as CFO, succeeding interim CFO Duke Drewell. The sale of its NeuroNOS subsidiary to XTL Biopharmaceuticals was halted. Steve Lisi resigned as CEO, and Robert Goodman was appointed as his successor. Beyond Air received a Nasdaq notice for failing to meet the minimum bid price requirement and faces potential delisting, with a special stockholder meeting scheduled to approve another reverse stock split. The stock has experienced a significant decline, trading near its 52-week low.